Evidence map›Paper›PMID 37150829›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.

Boting Ning, Andrew M Tilston-Lunel, Justice Simonetti, Julia Hicks-Berthet, Adeline Matschulat, Roxana Pfefferkorn, Avrum Spira, Matthew Edwards, Sarah Mazzilli, Marc E Lenburg and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Boting NingDepartment of Medicine, Computational Biomedicine Section, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Andrew M Tilston-LunelDepartment of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Room K620, Boston, MA, 02118, USA.
Justice SimonettiDepartment of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Room K620, Boston, MA, 02118, USA.
Julia Hicks-BerthetDepartment of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Room K620, Boston, MA, 02118, USA.
Adeline MatschulatDepartment of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Room K620, Boston, MA, 02118, USA.
Roxana PfefferkornDepartment of Medicine, Computational Biomedicine Section, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Avrum SpiraDepartment of Medicine, Computational Biomedicine Section, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Matthew EdwardsJohnson and Johnson Innovation, Cambridge, MA, 02142, USA.
Sarah MazzilliDepartment of Medicine, Computational Biomedicine Section, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
Marc E LenburgDepartment of Medicine, Computational Biomedicine Section, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA. mlenburg@bu.edu.
Jennifer E BeaneDepartment of Medicine, Computational Biomedicine Section, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA. jbeane@bu.edu.
Xaralabos VarelasDepartment of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Room K620, Boston, MA, 02118, USA. xvarelas@bu.edu.ORCID http://orcid.org/0000-0002-2882-4541
Boston University · USJohnson & Johnson (United States) · US

Funding

BIOLOGY OF THE LUNG--MULTIDISCIPLINARY PROGRAMT32HL007035 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton, JOSEPH P MIZGERD · 1985 to 2026
$24.3M
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary PremalignancyU2CCA233238 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DUBINETT, STEVEN M., SPIRA, AVRUM E · 2018 to 2021
$7.0M
Defining epithelial polarity cues that direct cell fateR01HL124392 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VARELAS, XARALABOS · 2014 to 2024
$4.5M
Enhancement and Cloud Deployment of CaDrA, a software tool for Candidate Driver Analysis of Multiomics DataR01DE030350 · NIDCR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KUKURUZINSKA, MARIA A., MONTI, STEFANO · 2021 to 2025
$3.2M
Defining molecular signals that influence airway basal cell renewal and growthF31HL149381 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MATSCHULAT, ADELINE MARIE · 2019 to 2023
$170k
Roles for YAP in multiciliogenesisF31HL132506 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BERTHET, JULIA · 2016 to 2019
$138k
NCI NIH HHS U2C CA233238NCI NIH HHS U2CCA233238NHLBI NIH HHS F31HL132506NHLBI NIH HHS F31 HL149381NHLBI NIH HHS F31HL149381NHLBI NIH HHS NIH R01HL124392NHLBI NIH HHS R01 HL124392NHLBI NIH HHS T32 HL007035NHLBI NIH HHS T32HL007035NIDCR NIH HHS R01 DE030350NIDCR NIH HHS R01DE030350
6 · The paper itself

Abstract

backgroundBronchial premalignant lesions (PMLs) are composed primarily of cells resembling basal epithelial cells of the airways, which through poorly understood mechanisms have the potential to progress to lung squamous cell carcinoma (LUSC). Despite ongoing efforts that have mapped gene expression and cell diversity across bronchial PML pathologies, signaling and transcriptional events driving malignancy are poorly understood. Evidence has suggested key roles for the Hippo pathway effectors YAP and TAZ and associated TEAD and TP63 transcription factor families in bronchial basal cell biology and LUSC. In this study we examine the functional association of YAP/TAZ, TEADs and TP63 in bronchial epithelial cells and PMLs.

methodsWe performed RNA-seq in primary human bronchial epithelial cells following small interfering RNA (siRNA)-mediated depletion of YAP/TAZ, TEADs or TP63, and combined these data with ChIP-seq analysis of these factors. Directly activated or repressed genes were identified and overlapping genes were profiled across gene expression data obtained from progressive or regressive human PMLs and across lung single cell RNA-seq data sets.

resultsAnalysis of genes regulated by YAP/TAZ, TEADs, and TP63 in human bronchial epithelial cells revealed a converged transcriptional network that is strongly associated with the pathological progression of bronchial PMLs. Our observations suggest that YAP/TAZ-TEAD-TP63 associate to cooperatively promote basal epithelial cell proliferation and repress signals associated with interferon responses and immune cell communication. Directly repressed targets we identified include the MHC Class II transactivator CIITA, which is repressed in progressive PMLs and associates with adaptive immune responses in the lung. Our findings provide molecular insight into the control of gene expression events driving PML progression, including those contributing to immune evasion, offering potential new avenues for lung cancer interception.

conclusionsOur study identifies important gene regulatory functions for YAP/TAZ-TEAD-TP63 in the early stages of lung cancer development, which notably includes immune-suppressive roles, and suggest that an assessment of the activity of this transcriptional complex may offer a means to identify immune evasive bronchial PMLs and serve as a potential therapeutic target.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsPrecancerous ConditionsGene Expression RegulationHumansSignal TransductionTEA Domain Transcription FactorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsTumor Suppressor ProteinsYAP-Signaling ProteinsTEA Domain Transcription FactorsTP63 protein, humanTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsTumor Suppressor ProteinsWWTR1 protein, humanYAP-Signaling ProteinsBronchial premalignant lesionsCIITAImmune evasionMHCIITAZTEADTP63YAP

Identifiers

PMID37150829
PMCPMC10165825
OpenAlexW4375855424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.